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and patients with end-stage renal disease.
Background.The metabolism of alpha and gamma tocoph-
erol, the major components of vitamin E, have not been studied
in uremic patients. The major pathway of tocopherol metabo-
lism is via phytyl side chain oxidation, leaving carboxyethyl-
hydroxychromans (CEHC) as metabolites. Alpha and gamma
CEHC are water soluble, renally excreted, with known potent
anti-inflammatory and antioxidative properties.
Methods.We examined serum alpha and gamma tocopherol
and respective CEHC concentrations in 15 healthy subjects
and 15 chronic hemodialysis patients.
Results. Serum alpha tocopherol levels were similar in he-
modialysis patients (12.03  1.34 g/mL) and healthy subjects
(11.21  0.20 g/mL), while serum gamma tocopherol levels
were significantly greater in hemodialysis patients (3.17  0.37
g/mL) compared to healthy subjects (1.08  0.06 g/mL, P
0.0001). Serum alpha and gamma CEHC levels were tenfold
and sixfold higher in hemodialysis patients compared to healthy
subjects, respectively (both P 0.0001). Serum alpha and gamma
tocopherol levels and CEHC metabolites were also measured
after supplementation of alpha- or gamma-enriched mixed to-
copherols in both hemodialysis patients and healthy subjects.
Tocopherol administration resulted in modest or nonsignificant
changes in serum tocopherol concentrations, while markedly
increasing serum CEHC concentrations in both healthy subjects
and hemodialysis patients. Hemodialysis resulted in no change
in the serum alpha or gamma tocopherol concentrations while
decreasing serum alpha CEHC and gamma CEHC levels by
63% and 53%, respectively (both P 0.001 versus predialysis).
Fourteen-day administration of gamma-enriched but not alpha
tocopherols lowered median C-reactive protein (CRP) signifi-
cantly in hemodialysis patients (4.4 to 2.1 mg/L, P  0.02).
Conclusion. First, serum alpha and gamma CEHC accumu-
late in uremic patients compared to healthy subjects; second,
supplementation with tocopherols dramatically increases serum
CEHC levels in both healthy subjects and hemodialysis patients;
and, finally, CEHC accumulation may mediate anti-inflamma-
tory and antioxidative effects of tocopherols in hemodialysis
patients.
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The uremic syndrome is increasingly recognized as an
increased oxidative stress state. The increased oxidation
of proteins, lipids, and carbohydrates imposed by the
uremic milieu is hypothesized to contribute to the accel-
erated development of atherogenesis [1–19]. This has
led to the suggestion that antioxidant therapy, particu-
larly with vitamin E, may reduce the oxidative stress
burden in the uremic milieu and thereby lower the rate of
cardiovascular events. The recently reported Secondary
Prevention with Antioxidants of Cardiovascular Events
(SPACE) Study, in which high-dose alpha tocopherol
lowered the rate of cardiovascular events in an end-stage
renal disease (ESRD) population, confirms the promise
of antioxidant therapy in this patient population [20].
However, the SPACE Study did not demonstrate a sig-
nificant reduction in mortality despite the reduction in
cardiovascular events and the optimal approach to anti-
oxidant therapy, including vitamin E in dialysis patients,
remains to be determined.
The term “vitamin E” is used to describe a family of
eight structurally related compounds consisting of alpha,
beta, gamma, and delta tocopherol and the correspond-
ing tocotrienols [21]. The tocopherols are characterized
by a differentially substituted chroman ring with an ac-
companying 16 carbon phytyl side chain (Fig. 1). Evi-
dence suggests that both alpha and gamma tocopherol
have important antioxidative and anti-inflammatory
properties and may play a preventative role in chronic
disease states associated with increased inflammation
and oxidative stress [22–24].
Since all natural tocopherols have a common saturated
phytyl side chain and a hydroxyl group on the chroman
ring, the major structural difference is in the number
and position of methyl groups on the chroman ring. The
two major antioxidant forms of tocopherols, alpha and
gamma tocopherol, differ structurally only by a methyl
group substitution at the five position. However, this
additional methyl group allows alpha tocopherol to be
bound by the tocopherol transfer protein, and preferen-
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Fig. 1. Structures of alpha, beta, gamma, and
delta tocopherols and alpha, beta, gamma, and
delta carboxyethyl-hydroxychromans (CEHCs).
tially exported from hepatocytes and incorporated into
lipoproteins, including low-density lipoproteins (LDL)
[25, 26]. In vitro studies demonstrate superior antioxi-
dant properties of alpha tocopherol in the prevention of
LDL lipid peroxidation due to its lipid solubility and
preferential incorporation into lipoproteins [27].
For many years, tocopherol metabolism was thought
to proceed via a free radical attack on the chroman struc-
ture resulting in the formation of a tocopherylquinone.
Degradation of the phytyl side chain would then lead to
the formation of alpha tocopheronic acid as well as the
so-called Simon metabolites, which can be glucuronidated
or sulfated and excreted in the urine [28, 29]. In the past
decade, the discovery of urinary tocopherol metabolites
with an intact chroman structure has been noted. These
carboxyethyl-hydroxychromans (CEHC) are now known
to be the major metabolites derived from each of the four
parent tocopherol compounds [30–32]. This pathway of
tocopherol metabolism derived from side chain degrada-
tion, leaves an intact chroman structure with potential
antioxidant activity (Fig. 1). Of importance, the CEHC
metabolites of tocopherols are water soluble and are
known to be at least partially renally excreted.
To date, there are very few studies examining human
tocopherol metabolism in vivo, and no published studies
examining differential tocopherol metabolism in patients
with ESRD. We therefore examined the metabolism of
both alpha tocopherol and gamma tocopherol in patients
with ESRD compared to age- and gender-matched healthy
subjects.
METHODS
Patient population
Fifteen patients on chronic maintenance hemodialysis
were recruited from hemodialysis units associated with
the Division of Nephrology at Maine Medical Center
and informed consent was obtained. Eligibility criteria
required subjects to be between the ages of 30 and 60
years, and to have clinically acceptable hepatic function
(transaminasestwice normal) and white blood cell counts
between 4500 and 10,500. Individuals were excluded if
they had chronic inflammatory diseases, evidence of re-
cent bacterial infection, were pregnant or lactating, had
clinically significant electrocardiogram (ECG) abnor-
malities, or a body mass index (BMI) 30 kg/m2. Anti-
inflammatory medications as well as alpha tocopherol
60 IU/day and vitamin C 500 mg/day supplements
were also prohibited. Subjects continued with all pre-
scribed medications as instructed by their physician for
the duration of the study. The mean age of dialysis pa-
tients was 49.8  1.9 years, with eight female and seven
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male subjects; seven of the patients were diabetic. Serum
albumin was 3.65  0.10 g/dL and Kt/Vurea was 1.38 
0.06. Fifteen subjects who were age- and gender-matched
healthy controls (mean age, 45.1  1.8 years; eight fe-
males, seven males) were also recruited for the study.
Informed consent was obtained from all study subjects.
Study protocols
Fifteen patients on chronic hemodialysis therapy and
15 healthy subjects were randomized to receive either
an alpha tocopherol preparation or a preparation en-
riched in gamma tocopherol in a double-blinded fashion.
The alpha and mixed tocopherol raw materials were
purchased from Cargill (Minneapolis, MN, USA) and
encapsulated by Soft Gel Technologies (Los Angeles,
CA, USA). The identical white soft gel capsules con-
tained either 99% RRR-alpha tocopherol or a mixture
of 60% RRR-gamma tocopherol, 28% RRR-delta to-
copherol, and 10% RRR-alpha tocopherol as measured
by liquid chromatography–mass spectometry. As there
is relatively sparse published information on the metabo-
lism of gamma tocopherol, subjects were allocated to
this vitamin E isomer in a 2:1 ratio relative to the more
comprehensively studied alpha tocopherol (i.e., ten dial-
ysis patients and ten healthy subjects receiving gamma-
enriched tocopherols versus five dialysis patients and five
healthy subjects receiving alpha tocopherol).
Each subject underwent two separate protocols after
randomization to a given type of tocopherol. In the first
protocol, each subject received a single 600 mg dose
of tocopherol preparation. Clinical laboratory measures
and analysis of tocopherol levels were assayed 1 day
before, and 1 and 6 days after the acute dose, respec-
tively. For hemodialysis patients, tocopherol assays were
also performed before and after dialysis on the day after
tocopherol administration.
In the second protocol (performed after at least a
2-week washout from the first protocol), both hemodialy-
sis patients and healthy subjects received a daily adminis-
tration of 300 mg of the blinded tocopherol preparation
for 14 consecutive days. Clinical parameters and labora-
tory assays were assessed at baseline, and after 7 and 14
days of tocopherol administration. Blood chemistries,
complete blood count with differential, and vital signs
were determined at each study visit. Serum alpha tocoph-
erol, gamma tocopherol, alpha CEHC, and gamma CEHC
were measured at all visits. Serum C-reactive protein
(CRP), interleukin-6 (IL-6), and prealbumin levels were
measured at the start and end of the 2-week dosing phase
of the study. For hemodialysis patients, at the 14-day
time point, blood samples were drawn pre- and postdial-
ysis for measurements of alpha tocopherol, gamma to-
copherol, alpha CEHC, and gamma CEHC. Patient safety
was assessed by physical examination, vital signs, clinical
laboratory evaluations, and reports of adverse events
throughout the study.
Tocopherol and CEHC analysis
Reagents. Gamma tocopherol and alpha tocopherol
were purchased from Sigma Chemical Co. (St. Louis, MO,
USA). Gamma and alpha tocopherol stock solutions
were prepared individually in acetonitrile (4 mg/mL)
and stored in amber vials at –80C. Gamma CEHC was
prepared at Galileo Laboratories, Inc. (Santa Clara, CA,
USA), while alpha CEHC was purchased from Encore
Pharmaceuticals (Riverside, CA, USA). Gamma and alpha
CEHC stock solutions were prepared individually in ace-
tonitrile (1 mg/mL) and stored in amber vials at –80C.
Acetonitrile and methanol used for extraction and high-
performance liquid chromatography (HPLC) were pur-
chased from Burdick and Jackson (Muskegon, MI, USA).
Acetic acid, ethanol, and hexane were obtained from
EM Science (Gibbstown, NJ, USA). Butylated hydroxy
toluene (BHT), l-ascorbic acid, Escherichia coli -glucu-
ronidase, trifluoroacetic acid, and monobasic potassium
phosphate were purchased from Sigma Chemical Co.
Pooled, frozen human serum and serum with ethylenedi-
aminetetraacetic acid (EDTA) used for background sub-
traction and standards was obtained from Valley Bio-
medical (Winchester, VA, USA). Centricon YM-30 and
YM-50 membrane filtration devices were obtained from
Millipore Corp. (Bedford, MA, USA).
Instruments. Tocopherol analyses were conducted by
liquid chromatography–ultraviolet detection on an Agi-
lent 1100 Series HPLC with diode array detector using
an Alltima C18 HPLC column (5 m, 150  2.1 mm)
purchased from Alltech Associates, Inc. (Deerfield, IL,
USA). CEHC analyses were conducted by liquid chro-
matography–mass spectrometry on an Agilent 1100 Se-
ries LC-MSD with diode array detector and electrospray
ionization (ESI) source using the same type of HPLC
column. Solvent removal was achieved using a Speedvac
SC210A centrifugal evaporator (Savant Instruments, Hol-
brook, NY, USA).
Tocopherol standards. Standard mixtures of gamma
and alpha tocopherol (1:1) in acetonitrile (10, 20, 50,
100, 500, 1000, and 2000 g/mL each) were prepared
from stock solutions on each day of analyses. Each stan-
dard mixture (10 L) was added to 90 L of pooled
human serum to produce samples used to generate the
standard curves (1, 2, 5, 10, 50, 100, and 200 g/mL
tocopherols).
Tocopherol extraction. Ethanol (150 L) was added
to each standard serum sample prepared as described
above and to each study subject serum sample (100 L)
to precipitate proteins, and then 250L water was added
to increase the volume for extraction. Tocopherols were
extracted with 2 mL of hexane/ethyl acetate (5:1). After
vortexing, centrifugation, and freezing the sample at –80C,
the upper, organic layer was removed and the solvents
evaporated. The residue was resuspended in 100 L of
acetonitrile/methanol (1:1) and used for HPLC analysis.
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Tocopherol analysis. Extracted tocopherols were sep-
arated by HPLC (25 L injection) using an Alltima C18
reversed-phase HPLC column (5 m, 150  2.1 mm)
eluted with acetonitrile/methanol (80:20) with trifluoro-
acetic acid (0.1%) at a flow rate of 0.3 mL/min. Ultraviolet
monitoring at 295 nm allowed detection of gamma and
alpha tocopherol at 11.1 and 12.9 minutes, respectively.
Tocopherol data analysis. Data to create standard
curves for gamma and alpha tocopherol was generated
by duplicate or triplicate analysis of standards prepared
as described above (1, 2, 5, 10, 50, 100, and 200 g/mL
tocopherols). For each sample, the integration of peaks
was generated from the chromatogram at 295 nm and
the background (extracted pooled human serum) was
subtracted. Curve fitting was performed in Microsoft
Excel. Linear or weighted (1/x or 1/x2) standard curves
of ultraviolet absorbance at 295 nm versus concentration
in g/mL were generated. Generally, the linear range
for quantitation for gamma and alpha tocopherol was 1
to 100 g/mL and the lower limit of quantitation (LLOQ)
was 1 g/mL. Tocopherol levels of samples from each
study subject were calculated using the standard curve
generated on the day of analysis.
CEHC standards. Standard mixtures of gamma and
alpha CEHC (1:1) in water (50, 100, 250, 500, 1000, and
5000 ng/mL each) were prepared from stock solutions
on each day of analysis. Each standard mixture (10 L)
was added to 90 L of pooled human serum to produce
samples used to generate the standard curves (5, 10, 25,
50, 100, 500 ng/mL CEHCs).
CEHC extraction. Ascorbic acid in water (10 L, 5
mg/mL) was added to each standard serum sample pre-
pared as described above and to each study subject serum
sample (100 L) to stabilize CEHCs, and then 100 L
-glucuronidase solution [7500 units/mL in 10 mmol/L
potassium phosphate buffer (pH 6.8)] was added to each
sample to liberate conjugated CEHCs. Following the
incubation period of 30 minutes at 37C, 800 L of meth-
anol containing 10 g/mL BHT was added to precipitate
protein and extract the CEHCs. After vortexing and
centrifugation, each supernatant was transferred to a
Centricon YM-30 or YM-50 membrane filtration device,
which had been prepared by addition of 1 mL of water.
Extracts were then centrifuged at 3700 rpm at 15C for
45 minutes to decontaminate the samples. Solvents were
removed from the filtrate and the residue was resus-
pended in 100 L 45% methanol–0.1% acetic acid con-
taining 50 g/mL ascorbic acid.
CEHC analysis. Extracted CEHCs were analyzed by
liquid chromatography–mass spectometry (30 L injec-
tion) using an Alltima C18 reversed-phase HPLC column
(5 m, 150  2.1 mm) eluted with a solvent gradient
starting in water (0.1% HOAc)/methanol (55:45) for 1
minute, followed by a linear gradient to 80% methanol at
10 minutes at a flow rate of 0.25 mL/min. These conditions
were maintained until 15 minutes when a quick (1⁄2 minute)
gradient to 100% methanol was used to wash the column
(held until 25 minutes). Monitoring the separation by
mass spectrometry using an ESI source operating in the
negative ion mode with selective ion monitoring (SIM)
at 263.1 atomic mass unit (amu) (gamma CEHC) and
277.1 amu (alpha CEHC) allowed detection of gamma
and alpha CEHC at 12.9 and 13.8 minutes, respectively.
CEHC data analysis. Data to create standard curves
for gamma and alpha CEHC was generated by duplicate
or triplicate analysis of standards prepared as described
above (5, 10, 25, 50, 100, 500 ng/mL). For each sample,
the integration of peaks was generated from the SIM
chromatogram at 263.1 amu (gamma CEHC) and 277.1
amu (alpha CEHC), and the background (extracted
pooled human serum) was subtracted. Curve fitting was
performed in Microsoft Excel. Linear or weighted (1/x
or 1/x2) standard curves of SIM peak area versus concen-
tration in ng/mL were generated. Generally, the linear
range for quantitation was 10 to 500 ng/mL or 5 to 500
ng/mL and the LLOQ was 10 and 5 ng/mL for gamma
and alpha CEHC, respectively. Samples measured above
the linear range were diluted tenfold with pooled human
serum and analyzed. CEHC levels of samples from each
study subject were calculated using the standard curve
generated on the day of analysis.
Laboratory analysis
Complete blood counts were determined using an
EPEX Coulter Counter (Miami, FL, USA). Compre-
hensive metabolic profiles were measured using an auto-
analyzer. High-resolution CRP was determined using
nepholometry. Prealbumin was determined using an auto-
analyzer. Serum IL-6 levels were determined by enzyme-
linked immunosorbent assay (ELISA).
Statistical analyses
Wilcoxon signed rank tests were performed for within
group comparisons, and Mann-Whitney U tests were per-
formed for between group comparisons. The Spearman
rank correlation test was used to measure the association
between serum CRP and IL-6. Fisher’s exact test was
used to compare the incidence of adverse experiences
among treatment groups. These analyses were carried
out using Intercooled Stata 6.0 for Windows 98/85/NT
(Stata Corporation, College Station, TX, USA). Data
are reported as means  SEM unless otherwise noted.
RESULTS
Baseline tocopherol and CEHC levels
Serum alpha tocopherol, gamma tocopherol, alpha
CEHC, and gamma CEHC levels were determined in all
15 healthy subjects and 15 hemodialysis patients. Serum
alpha tocopherol levels were significantly higher than
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Table 1. Baseline concentration of serum tocopherols and carboxyl-
hydroxvchromans (CEHCs) [means 	 SEM (median)]
Serum level Healthy subjects Hemodialysis patients
Alpha tocopherol
ug/mL 11.210.20 (11.09)a 12.031.34 (12.53)a
Gamma tocopherol
ug/mL 1.080.06 (1.08)b 3.170.37 (3.41)
Alpha CEHC
ng/mL 7.431.31 (6.63)b,c 75.6517.06 (52.87)c
Gamma CEHC
ng/mL 95.3018.79 (74.22)b 582.21120.35 (450.58)
aP  0.0001 vs. gamma tocopherol (within column)
bP  0.0001 vs. hemodialysis patients (within row)
cP  0.0001 vs. gamma CEHC (within column)
gamma tocopherol levels in both healthy subjects (11.21
0.20 g/mL versus 1.08  0.06 g/mL, P  0.0001) and
hemodialysis patients (12.03  1.34 g/mL versus 3.17 
0.37 g/mL, P  0.0001) (Table 1). There were no sig-
nificant differences in alpha tocopherol levels between
healthy subjects and hemodialysis patients (P  0.46).
In contrast, serum gamma tocopherol levels were sig-
nificantly greater in hemodialysis patients than healthy
subjects (P  0.0001).
Both serum alpha and gamma CEHC levels were mark-
edly greater in hemodialysis patients than healthy sub-
jects. Alpha CEHC levels were tenfold higher in the
hemodialysis group compared to healthy subjects (75.65
17.06 ng/mL versus 7.43  1.31 ng/mL, P  0.0001).
Similarly, serum gamma CEHC levels were sixfold
higher in the hemodialysis patients compared to healthy
subjects (582.21  120.35 ng/mL versus 95.30  18.79
ng/mL, P  0.0001). In both healthy subjects and hemo-
dialysis patients, serum gamma CEHC was significantly
higher than serum alpha CEHC levels (P  0.0001).
Metabolism of a single dose of 600 mg alpha
tocopherol administration
The effect of the administration of a single 600 mg
dose of alpha tocopherol was examined in five healthy
subjects and five hemodialysis patients. Figure 2A dem-
onstrates there were no significant changes in either se-
rum alpha tocopherol or serum gamma tocopherol levels
on either day 1 or day 6 after alpha tocopherol adminis-
tration in healthy subjects or hemodialysis patients.
Figure 2B demonstrates that in healthy subjects, there
was a nonsignificant increase in alpha CEHC levels on
day 1 after alpha tocopherol administration (9.66  3.64
ng/mL versus 19.44  6.62 ng/mL, P  0.14), which
diminished by day 6 (9.66  3.64 ng/mL versus 15.10 
5.38 ng/mL, P  0.35). Of interest, alpha tocopherol
administration was also associated with a nonsignificant
decrease in serum gamma CEHC levels on day 6 after
administration to healthy subjects compared to prior to
administration (151.58  47.11 ng/mL versus 85.65 
30.86 ng/mL, P  0.35). In hemodialysis patients, single-
dose alpha tocopherol administration was not associated
with a significant change in either serum alpha CEHC
or gamma CEHC levels.
Effect of a single dose of 600 mg of
gamma-enriched tocopherols
A single 600 mg dose of a gamma tocopherol–enriched
preparation was administered to 10 healthy subjects and
10 hemodialysis patients. Figure 3A demonstrates that
in healthy subjects, gamma tocopherol administration
was associated with a significant increase in serum gamma
tocopherol levels on day 1 (1.09  0.06 g/mL versus
2.06  0.15 g/mL, P  0.005) and day 6 (1.09  0.06
g/mL versus 1.74 0.25 g/mL, P 0.04) after admin-
istration, with no significant changes observed in serum
alpha tocopherol levels. In hemodialysis patients, gamma
tocopherol administration resulted in a significant in-
crease in serum gamma tocopherol levels at day 1 after
administration (3.38  0.52 g/mL versus 5.17  0.53
g/mL, P  0.04), which was no longer evident at day 6.
No significant effects on serum alpha tocopherol levels
were observed.
In healthy subjects, the administration of a gamma
tocopherol–enriched preparation resulted in a marked
increase in serum gamma CEHC levels day 1 after ad-
ministration (67.16  8.16 ng/mL versus 348.45  79.00
ng/mL, P  0.005) (Fig. 3B). Of interest, by day 6 after
administration of a single dose, serum gamma CEHC
levels had returned to baseline levels in healthy subjects
(67.16  8.16 ng/mL versus 69.96  11.56 ng/mL, P 
0.72). In hemodialysis patients, the administration of a
single 600 mg dose of gamma tocopherol–enriched prep-
aration also resulted in a significant increase in serum
gamma CEHC levels at day 1 after administration
(730.82 159.47 ng/mL versus 1,848.04 349.91 ng/mL,
P 0.009). By day 6 after gamma tocopherol administra-
tion, serum gamma CEHC levels were no longer signifi-
cantly different from baseline (730.82  159.47 ng/mL
versus 1036.45 242.38 ng/mL, P 0.07). Alpha CEHC
levels did not vary in this patient population after admin-
istration of a single dose of gamma-enriched tocopherols.
Tocopherol metabolism during a 14-day course of
300 mg alpha tocopherol daily
Figure 4A demonstrates the effect of a 14-day adminis-
tration of alpha tocopherol on alpha tocopherol, gamma
tocopherol, alpha CEHC, and gamma CEHC levels in
healthy subjects and hemodialysis patients. In healthy
subjects, the administration of alpha tocopherol did not
result in a significant change in serum alpha tocopherol
levels after 7 days or 14 days of administration. However,
after 14 days of alpha tocopherol administration, serum
gamma tocopherol decreased significantly (2.60  0.73
g/mL versus 1.41  0.40 g/mL, P  0.04). Similarly,
in hemodialysis patients, alpha tocopherol administra-
tion did not result in a significant change in serum alpha
Himmelfarb et al: Tocopherol metabolism in ESRD 983
Fig. 2. Serum alpha and gamma tocopherol (A ) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B ) levels in healthy controls and
hemodialysis patients after a 600 mg dose of alpha tocopherol at day 0.
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Fig. 3. Serum alpha and gamma tocopherol (A ) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B ) levels in healthy controls and
hemodialysis patients after a 600 mg dose of gamma-enriched tocopherols at day 0.
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Fig. 4. Serum alpha and gamma tocopherol (A ) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B ) levels in healthy controls and
hemodialysis patients during a 14-day course of 300 mg alpha tocopherol/day.
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tocopherol levels on either day 7 or day 14. However,
after 7 and 14 days of alpha tocopherol administration,
serum gamma tocopherol levels decreased significantly
(1.36  0.20 g/mL versus 0.73  0.14 g/mL, P  0.04;
1.36  0.20 g/mL versus 0.72  0.10 g/mL, P  0.04,
respectively).
In healthy subjects, alpha tocopherol administration
did result in a significant increase in serum alpha CEHC
levels at day 7 (10.63  2.86 ng/mL versus 49.24  22.08
ng/mL, P  0.04) and day 14 (10.63  2.86 ng/mL versus
35.93 14.76 ng/mL, P 0.04), while not affecting serum
gamma CEHC levels (Fig. 4B). In hemodialysis patients,
alpha tocopherol administration also significantly increased
serum alpha CEHC levels at day 7 (56.43  3.13 ng/mL
versus 267.33 35.06 ng/mL, P 0.04) and day 14 (56.43
3.13 ng/mL versus 354.42  73.51 ng/mL, P  0.04).
Serum gamma CEHC levels were significantly greater
after 14 days of alpha tocopherol administration (393.21
67.85 ng/mL versus 623.16  204.25 ng/mL, P  0.04).
Thus, in both healthy subjects and hemodialysis patients,
the major metabolic effect of alpha tocopherol adminis-
tration was an increase in serum alpha CEHC levels
without a change in serum alpha tocopherol levels, al-
though minor effects on serum gamma tocopherol and
gamma CEHC cannot be ruled out.
Tocopherol metabolism during a 14-day course of
300 mg gamma-enriched tocopherols daily
Figure 5A depicts serum alpha tocopherol, gamma
tocopherol, alpha CEHC, and gamma CEHC levels after
a 2-week administration of daily gamma-enriched to-
copherol preparation. In healthy subjects, the adminis-
tration of gamma-enriched tocopherols did not signifi-
cantly change serum alpha tocopherol levels on day 7 or
14, but did result in a slight but significant increase in
serum gamma tocopherol levels at day 7 (2.72  0.39
g/mL versus 5.50  0.99 g/mL, P  0.03) and day 14
(2.72 0.39 g/mL versus 4.01 0.43 g/mL, P 0.02).
In hemodialysis patients, the administration of gamma
tocopherol–enriched preparation for 14 days did not sig-
nificantly affect alpha tocopherol levels or serum gamma
tocopherol levels at day 7 (2.18  0.40 g/mL versus
3.89  0.86 g/mL, P  0.13) or at day 14 (2.18  0.40
g/mL versus 3.30  0.70 g/mL, P  0.20).
The administration of gamma tocopherol–enriched
preparation resulted in a significant increase in serum
gamma CEHC levels in healthy subjects at day 7 (66.95
8.31 ng/mL versus 346.95 69.80 ng/mL, P 0.005) and
at day 14 (66.95  8.31 ng/mL versus 280.47  82.25
ng/mL, P  0.007). Gamma tocopherol administration
was associated with a significant increase in serum alpha
CEHC levels in healthy subjects at day 7 (5.16  0.49
ng/mL versus 7.67  1.43 ng/mL, P  0.03) but not day
14 (P  0.20). In hemodialysis patients, the administra-
tion of gamma tocopherol similarly resulted in a marked
increase in serum gamma CEHC levels at day 7 (749.22
175.82 ng/mL versus 3892.57 987.59 ng/mL, P 0.005)
and at day 14 (749.22  175.82 ng/mL versus 3395.44 
964.70 ng/mL, P 0.005). Of interest, gamma tocopherol–
enriched administration was also associated with signifi-
cant elevations in serum alpha CEHC levels in hemodial-
ysis patients at day 7 (41.54 13.08 ng/mL versus 120.98
35.49 ng/mL, P 0.005) and day 14 (41.54 13.08 ng/mL
versus 109.12  41.09 ng/mL, P  0.005).
Effects of the hemodialysis procedure on
tocopherol metabolism
The effects of the hemodialysis procedure on the clear-
ance of serum alpha tocopherol, gamma tocopherol,
alpha CEHC, and gamma CEHC was also examined
both after the administration of a single 600 mg dose
and after a 2-week course of 300 mg of the corresponding
tocopherols. There was no significant effect of the dialysis
procedure on serum gamma tocopherol levels (2.44 
0.56 g/mL versus 2.37  0.47 g/mL, P  0.64), nor
serum alpha tocopherol (8.00  1.30 g/mL versus 8.55
1.71 g/mL, P  0.58) (Table 2). Serum alpha CEHC
levels decreased by 63% (190.88  46.83 ng/mL versus
70.80 	 18.34 ng/mL) and serum gamma CEHC levels
decreased by 53% after the dialysis procedure (2471.35
724.44 ng/mL versus 1163.83  321.56 ng/mL, in both
cases P  0.001 versus predialysis). These data suggest
that the water-soluble CEHC metabolites of tocopherols
are readily dialyzable, while the more lipid-soluble parent
compounds are not.
Effects of tocopherol administration on the acute-phase
inflammatory process
It has recently been suggested that gamma tocopherol
and its metabolite gamma CEHC may have potent anti-
inflammatory effects, which are not shared by alpha to-
copherol. We therefore compared the effects of a 2-week
administration of alpha tocopherol and gamma-enriched
tocopherols on serum CRP and serum IL-6 levels. For this
analysis, a patient receiving gamma-enriched tocopherols
who had an intercurrent hospitalization with surgery in
the midst of the study was excluded from analysis. Figure
6B demonstrates that for hemodialysis patients taking
daily gamma-enriched tocopherols for 2 weeks, median
CRP declined from 4.4 to 2.1 mg/L (P  0.02). Although
there was a correlation between serum CRP and serum
IL-6 at day 0 (rho  0.98, P  0.0001) and day 14 (rho 
0.89, P 0.001), median serum IL-6 levels did not decline
significantly (12.6 versus 10.9 pg/mL, P 0.59) (Fig. 7B).
In the five hemodialysis patients who received a 2-week
course of alpha tocopherol therapy, there was no evi-
dence of a difference in median serum CRP (12.2 versus
10.8 mg/L, P  0.69) (Fig. 6A), while median serum IL-6
levels increased over the course of therapy (21.0 versus
32.9 pg/mL, P  0.04) (Fig. 7A).
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Fig. 5. Serum alpha and gamma tocopherol (A ) and alpha and gamma carboxyethyl-hydroxychroman (CEHC) (B ) levels in healthy controls and
hemodialysis patients during a 14-day course of 300 mg gamma-enriched tocopherols/day.
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Table 2. Effect of hemodialysis on serum tocopherols and
carboxyethyl-hydroxychromans (CEHCs)
[means 	 SEM (median)]
Serum level Before dialysis After dialysis
Alpha tocopherol ug/mL 8.001.30 8.551.71
(5.27) (6.56)
Gamma tocopherol ug/mL 2.440.56 2.370.46
(1.48) (1.83)
Alpha CEHC ng/mL 190.8846.83 70.8018.34
(105.29)a (37.87)
Gamma CEHC ng/mL 2471.35724.44 1163.83321.56
(1428.15)a (501.02)
aP  0.001 vs. after dialysis (within row)
DISCUSSION
The term “vitamin E” was introduced by Evans and
Bishop [33] in 1922 to describe a micronutrient essential
for reproduction in rats. It took over 40 years after its
discovery before recognition of the antioxidant proper-
ties of vitamin E [34], and another 25 years for the nonox-
idative properties to be discovered [35, 36]. Detailed
information concerning tissue distribution of vitamin E
and its metabolites has only begun to be determined
over the past 5 years.
The recognition that lipoprotein oxidation within the
vascular wall plays a central role in the progression of
atherogenesis has led to interest in examining the poten-
tial efficacy of tocopherols as antiatherogenic molecules
[27]. Epidemiologic studies have reported that high vita-
min E intakes are correlated with a reduced risk of car-
diovascular disease in contrast to other dietary antioxi-
dants such as ascorbic acid and beta carotene. However,
while two large epidemiologic studies in the United
States have found significant risk reduction in association
with high alpha tocopherol intake [37, 38], three large
prospective, nested, case-control studies have not been
able to correlate serum alpha tocopherol concentrations
with subsequent cardiovascular events [39–41]. Of inter-
est, serum gamma tocopherol levels have been more
consistently associated in observational studies with de-
creased cardiovascular disease risk than serum alpha to-
copherol levels [42–44].
In this study, baseline serum alpha tocopherol levels
were not significantly different between healthy subjects
and patients receiving chronic hemodialysis therapy.
Several recent studies have also demonstrated similar
serum alpha tocopherol levels in chronic hemodialysis
patients compared to healthy subjects [4, 45–51]. The
finding of increased serum gamma tocopherol levels in
hemodialysis patients compared to healthy subjects was
surprising and suggests that either gamma tocopherol
metabolism or renal excretion of the parent compound
is affected by renal failure. To our knowledge, this is the
first study to measure serum gamma tocopherol levels
in hemodialysis patients.
The administration of alpha tocopherol either as a
single high dose or as a 14-day course did not affect
serum alpha tocopherol levels in either healthy subjects
or hemodialysis patients. These data are in accordance
with previous studies suggesting that serum alpha to-
copherol concentration is saturable, resulting in an in-
crease in metabolism to alpha CEHC. In fact, in healthy
subjects, it has previously been suggested that measure-
ments of urinary alpha CEHC can be used as a biomarker
of adequate tissue alpha tocopherol stores [31]. Of poten-
tial importance, however, the administration of a 14-
day course of alpha tocopherol resulted in a significant
decrease in serum gamma tocopherol levels in healthy
subjects and hemodialysis patients. These data are in
accord with previous studies suggesting that alpha to-
copherol can replace gamma tocopherol in lipid mem-
branes and vice versa [52, 53]. Thus, biologic interactions
between different tocopherol preparations would sug-
gest that supplementation with mixed tocopherols (i.e.,
akin to “natural” or dietary tocopherols) may potentially
avoid adverse biologic effects.
In contrast to alpha tocopherol, administration of a
gamma tocopherol–enriched preparation resulted in sig-
nificant increases in serum gamma tocopherol levels in
healthy subjects. This suggests that serum gamma to-
copherol levels are more modifiable by supplementation
and may perhaps explain why observational studies have
correlated serum gamma tocopherol levels with cardio-
vascular disease more consistently than serum alpha to-
copherol levels [42–44]. Because the gamma tocopherol–
enriched preparation also contained alpha tocopherol,
it is impossible to tell from these studies whether admin-
istration of pure gamma tocopherol would affect serum
alpha tocopherol levels.
A remarkable finding in this study is the dramatically
elevated serum alpha and gamma CEHC levels in hemo-
dialysis patients compared to healthy subjects. To our
knowledge, there are only two previous studies in the
literature measuring serum alpha and gamma CEHC
levels in humans, and neither study examined patients
with renal disease [54, 55]. The finding of six- to tenfold
higher alpha and gamma CEHC levels in hemodialysis
patients compared to healthy subjects confirms the im-
portant role of urinary excretion of the water-soluble
metabolites of tocopherols in healthy subjects. Since the
CEHC metabolites of tocopherols may have important
biologic activities [23], these data strongly suggest that
studies administering antioxidants to patients with renal
failure must take into account antioxidant metabolism
as part of study design. The finding that in both healthy
subjects and hemodialysis patients, serum gamma CEHC
concentrations are markedly higher than alpha CEHC
concentrations, while conversely serum alpha tocopherol
levels are markedly higher than serum gamma tocoph-
erol levels, points to the crucial importance of the hepatic
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Fig. 6. C-reactive protein (CRP) after 14 days
of (A ) alpha-enriched tocopherol or (B )
gamma-enriched tocopherol. Symbols are: ()
individual patients; () mean of all patients.
Fig. 7. Interleukin-6 (IL-6) in hemodialysis patients at day 0 and day 14
of (A ) alpha-enriched tocopherol or (B ) gamma-enriched tocopherol.
Symbols are: () individual patients; () mean of all patients. Day 0
vs. day 14, P  0.04.
tocopherol transport protein in differentiating the meta-
bolic fate of tocopherols [25, 26].
In both healthy subjects and hemodialysis patients, the
predominant effect of either alpha or gamma tocopherol
administration is on serum levels of the corresponding
CEHC metabolite rather than parent compounds. A pro-
vocative hypothesis stemming from this observation is
that the major biologic effects associated with adminis-
tration of high doses of tocopherols may also be mediated
through the CEHC metabolites. Since the tissue distribu-
tion of the water-soluble CEHC metabolites differs
markedly from the more lipid-soluble parent tocopher-
ols, this would suggest that administration of high-dose
tocopherols will affect extracellular and intracellular an-
tioxidant status more than lipoproteins and cell mem-
branes. In this context, it is tempting to speculate that
the beneficial effects seen in the SPACE Trial, where
high-dose alpha tocopherol was administered to hemodi-
alysis patients for a prolonged time course, may have
been due to the likely buildup of serum alpha CEHC
levels rather than to the effects of alpha tocopherol in
this patient population. Since serum CEHC accumulates
to a greater degree in renal failure, the relative potency
of tocopherol administration would be enhanced in the
presence of renal failure due to decreased renal clear-
ance of CEHC metabolites. In this context, it is worth
noting that, whereas in the general population studies
of alpha tocopherol administration have generally had
mixed results [56], studies in patients with ESRD have
almost invariably reported some potent and beneficial
biologic effects [20, 45, 46, 57–62].
A potentially important observation in this study is
that the administration of the gamma tocopherol–enriched
preparation, but not the alpha tocopherol preparation,
significantly reduced CRP concentrations in hemodialy-
sis patients. Although we did not observe a consistent
reduction in CRP with alpha tocopherol, we cannot rule
out a similar effect from this form of the vitamin due to
the small number of subjects given alpha tocopherol.
While alpha tocopherol is a potent lipoprotein and cell
membrane–associated antioxidant, several recent studies
have demonstrated that gamma tocopherol and gamma
CEHC may additionally function as potent anti-inflam-
matory agents in vitro. Both gamma tocopherol and
gamma CEHC at physiologically relevant concentrations
inhibit the cyclooxygenase-2 (COX-2) enzyme in macro-
phages and epithelial cells to a much greater degree than
alpha tocopherol [23]. Gamma tocopherol is also highly
potent in quenching reactive nitrogen species [63, 64].
It is important, however, to recognize that the sample
size in the present study, while sufficient to understand
the metabolism of tocopherols in healthy subjects and
patients with renal disease, may not be sufficient to allow
definitive interpretation of their relative efficacy as in
vivo anti-inflammatory agents. Similarly, the observation
of a slight increase in serum IL-6 levels after alpha to-
copherol administration is in contradistinction to other
studies in diabetic patients and may reflect the relatively
small sample size in the present study [65].
In this study, the hemodialysis procedure had no sig-
nificant effect on either serum alpha tocopherol or gamma
tocopherol levels. In contrast, hemodialysis resulted in
a 63% reduction in serum alpha CEHC levels and a 53%
reduction in gamma CEHC levels. Significant dialytic
clearance of alpha and gamma CEHC is to be expected
given their low molecular weight and water solubility,
whereas both parent compounds are highly lipid-soluble
and thus significant dialytic clearance is not expected.
Several limitations to the present study are acknowl-
edged. The liquid chromatography–mass spectometry
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assay employed in this study to measure extracted CEHC
concentrations does not discriminate between free and
glucuronidated CEHC. As a consequence, it is not possi-
ble to determine the extent to which the measured in-
crease in CEHCs in dialysis patients are bioactive in
the circulation. However, in the only published study
measuring both free and glucuronidated serum CEHCs,
only 35% of alpha CEHC and a trivial proportion of
gamma CEHC was glucuronidated [54]. The results are
consistent with the hypothesis that CEHC accumulation
could contribute to an anti-inflammatory and antioxida-
tive effect in uremic patients. An additional limitation
of the present study is the small sample size with respect
to inflammatory biomarkers. Further studies with larger
patient sample sizes will be required to more definitively
address these important end points.
CONCLUSION
This is the first study to examine the metabolism of
alpha and gamma tocopherol, the two major components
of vitamin E, in both healthy subjects and hemodialysis
patients. The tocopherol metabolites alpha and gamma
CEHC accumulate in the serum of uremic patients com-
pared to healthy subjects, and supplementation with to-
copherols dramatically increases serum CEHC levels in
both healthy subjects and hemodialysis patients. Admin-
istration of gamma- but not alpha-enriched tocopherols
to maintenance hemodialysis patients significantly re-
duced median serum CRP. Further studies assessing the
potential anti-inflammatory and antioxidative effects of
tocopherol administration in uremic patients are required.
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